Novavax Soars 80% After COVID-19 Vaccine Funding and Earnings

Novavax, a clinical-stage biotechnology company shares soared over 80% Monday after NVAX received a $384 million investment for its COVID-19 vaccine candidate and beat Wall Street earnings expectations for first quarter earnings. Novavax said the Coalition for Epidemic Preparedness Innovations will invest up to $384 million in the development of NVX-CoV2373, Novavax’s vaccine candidate for SARS-CoV-2, the coronavirus that causes COVID-19. Funding will be used for combined safety and effectiveness testing of the vaccine, Novavax said. Market Summary > Novavax, … Continue reading “Novavax Soars 80% After COVID-19 Vaccine Funding and Earnings”